We are currently conducting biochemical studies and analysing additional ovarian cancer samples, as well as patient-derived xenografts, enriched for BRCA1/2 mutants, to understand whether the BRCA1/2 mutational status is associated with or determines the CCDC6 increased turnover. The gene discussed is BRCA1; the disease is ovarian carcinoma.